IL15 levels on day 7 after hematopoietic cell transplantation predict chronic GVHD

Bone Marrow Transplantation

Volumn 48, Issue 5, 2013, Pages 722-728

  Pratt, L M ^a   Liu, Y ^a   Ugarte Torres, A ^a,b   Hoegh Petersen, M ^a   Podgorny, P J ^a   Lyon, A W ^a,b   Williamson, T S ^a   Khan, F M ^a,b   Chaudhry, M A ^b   Daly, A ^b   Stewart, D A ^a,b   Russell, J A ^b   Grigg, A ^c   Ritchie, D ^c   Storek, J ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b ALBERTA HEALTH SERVICES   (Canada)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

CD8 T cells; chronic GVDH; hematopoietic cell transplantation; IL15

Indexed keywords

B CELL ACTIVATING FACTOR; BUSULFAN; CHOLINESTERASE; CYTARABINE; FLUDARABINE; GAMMA GLUTAMYLTRANSFERASE; INTERLEUKIN 15; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; METHOTREXATE; PROTEIN; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UREA; VASCULOTROPIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; HLA MATCHING; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATURAL KILLER CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

ADULT; AGED; CHRONIC DISEASE; COHORT STUDIES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERLEUKIN-15; LEUKEMIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; YOUNG ADULT;

EID: 84877667038     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.210     Document Type: Article

References (45)

1. Pavletic SZ, Vogelsang GB. Chronic graft-vs-host disease: clinical manifestations and therapy. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG (eds). Thomas' Hematopoietic Cell Transplantation. Blackwell Publishing, 2009, pp 1304-1324.
2. Socie G, Ritz J, Martin PJ. Current challenges in chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010; 16(1 Suppl): S146-S151.
3. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007; 7: 340-352.
4. Martin PJ, Pavletic SZ. Biology and management of chronic graft-versus-host disease. Cancer Treat Res 2009; 144: 277-298.
5. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
6. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956.
7. Inamoto Y, Flowers ME. Treatment of chronic graft-versus-host disease in 2011. Curr Opin Hematol 2011; 18: 414-420.
8. Lee SJ. Have we made progress in the management of chronic graft-vs-host disease? Best Pract Res Clin Haematol 2010; 23: 529-535.
9. Holler E. Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment. Best Pract Res Clin Haematol 2007; 20: 281-294.
10. Marsh JC, Gupta V, Lim Z, Ho AY, Ireland RM, Hayden J et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011; 118: 2351-2357.
11. Malladi RK, Peniket AJ, Littlewood TJ, Towlson KE, Pearce R, Yin J et al. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML. Bone Marrow Transplant 2009; 43: 709-715.
12. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR et al. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009; 10: 855-864.
13. Schattenberg A, van der Meer A, Preijers F, Schaap N, Rinkes M, van der Maazen R et al. Addition of ATG to the conditioning regimen is a major determinant for outcome after transplantation with partially lymphocyte-depleted grafts from voluntary unrelated donors. Bone Marrow Transplant 2004; 33: 1115-1121.
14. Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12: 560-565.
15. Socie G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATGFresenius. Blood 2011; 117: 6375-6382.
16. Hoegh-Petersen M, Amin MA, Liu Y, Ugarte-Torres A, Williamson TS, Podgorny PJ et al. Anti-thymocyte globulins capable of binding to T and B cells reduce graftvs-host disease without increasing relapse. Bone Marrow Transplant 2013; 48: 105-114.
17. Levine JE, Paczesny S, Sarantopoulos S. Clinical applications for biomarkers of acute and chronic graft-versus-host disease. Biol Blood Marrow Transplant 2012; 18(1 Suppl): S116-S124.
18. Flowers MED, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011; 117: 3214-3219.
19. Rozmus J, Schultz KR. Biomarkers in chronic graft-versus-host disease. Expert Rev Hematol 2011; 4: 329-342.
20. Bacigalupo A, Lamparelli T, Milone G, Sormani MP, Ciceri F, Peccatori J et al. Pre-emptive treatment of acute GVHD: a randomized multicenter trial of rabbit anti-thymocyte globulin, given on day\+7 after alternative donor transplants. Bone Marrow Transplant 2010; 45: 385-391.
21. Paczesny S, Krijanovski OI, Braun TM, Choi SW, Clouthier SG, Kuick R et al. A biomarker panel for acute graft-versus-host disease. Blood 2009; 113: 273-278.
22. Thiant S, Yakoub-Agha I, Magro L, Trauet J, Coiteux V, Jouet JP et al. Plasma levels of IL-7 and IL-15 in the first month after myeloablative BMT are predictive biomarkers of both acute GVHD and relapse. Bone Marrow Transplant 2010; 45: 1546-1552.
23. Cho B-S, Min C-K, Kim H-J, Lee S, Kim YJ, Lim JY et al. High levels of B cell activating factor during the peritransplantation period are associated with a reduced incidence of acute graft-versus-host disease following myeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2010; 16: 629-638.
24. Thiant S, Labalette M, Trauet J, Coiteux V, de Berranger E, Dessaint JP et al. Plasma levels of IL-7 and IL-15 after reduced intensity conditioned allo-SCT and relationship to acute GVHD. Bone Marrow Transplant 2011; 46: 1374-1381.
25. Toubai T, Tanaka J, Paczesny S, Shono Y, Reddy P, Imamura M. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD)-Are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (allo-HCT)? Curr Stem Cell Res Ther 2012; 7: 229-239.
26. Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood 2009; 113: 3865-3874.
27. Fujii H, Cuvelier G, She K, Aslanian S, Shimizu H, Kariminia A et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group. Blood 2008; 111: 3276-3285.
28. Kobayashi S, Imamura M, Hashino S, Tanaka J, Asaka M. Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versus-host disease. Leuk Lymphoma 1997; 28: 159-169.
29. Liem LM, van Houwelingen HC, Goulmy E. Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation 1998; 66: 863-871.
30. Sormani MP, Oneto R, Bruno B, Fiorone M, Lamparelli T, Gualandi F et al. A revised day \+7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, [gamma] glutamyl transferase, donor type and cell dose. Bone Marrow Transplant 2003; 32: 205-211.
31. Podgorny PJ, Ugarte-Torres A, Liu Y, Williamson TS, Russell JA, Storek J. High rabbit-antihuman thymocyte globulin levels are associated with low likelihood of graft-vs-host disease and high likelihood of posttransplant lymphoproliferative disorder. Biol Blood Marrow Transplant 2010; 16: 915-926.
32. Remberger M, Sundberg B. Low serum levels of total rabbit-IgG is associated with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation: results from a prospective study. Biol Blood Marrow Transplant 2009; 15: 996-999.
33. Horowitz M, Gale R, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graftversus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
34. Signori A, Crocchiolo R, Oneto R, Sacchi N, Sormani MP, Fagioli F et al. Chronic GVHD is associated with inferior relapse risk irrespective of stem cell source among patients receiving transplantation from unrelated donors. Bone Marrow Transplant 2012; 47: 1474-1478.
35. Jakobisiak M, Golab J, Lasek W. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev 2011; 22: 99-108.
36. Di Sabatino A, Calarota SA, Vidali F, Macdonald TT, Corazza GR. Role of IL-15 in immune-mediated and infectious diseases. Cytokine Growth Factor Rev 2011; 22: 19-33.
37. Bosch M, Dhadda M, Hoegh-Petersen M, Liu Y, Hagel LM, Podgorny P et al. Immune reconstitution after antithymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy 2012; 14: 1258-1275.
38. Kinter AL, Godbout EJ, McNally JP, Sereti I, Roby GA, O'Shea MA et al. The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands. J Immunol 2008; 181: 6738-6746.
39. Yang J, Riella LV, Chock S, Liu T, Zhao X, Yuan X et al. The novel costimulatory programmed death ligand 1/B7.1 pathway is functional in inhibiting alloimmune responses in vivo. J Immunol 2011; 187: 1113-1119.
40. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-2100.
41. Shlomchik WD, Couzens MS, Tang CB, Tang CB, McNiff J, Robert ME et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412-415.
42. Chen G, Wu D, Wang Y, Cen J, Feng Y, Sun A et al. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation. Eur J Haematol 2008; 81: 226-235.
43. Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D et al. Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. Biol Blood Marrow Transplant 2006; 12: 573-584.
44. Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reducedintensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117: 6963-6970.
45. Devillier R, Crocchiolo R, Castagna L, Fürst S, El Cheikh J, Faucher C et al. The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone Marrow Transplant 2012; 47: 639-645.